AnaptysBio to Spin Off Biopharma Unit as First Tracks Biotherapeutics in Q2 2026 to Unlock Value
ANAB has more than doubled off its 52-week low of $13.99.
Summary
AnaptysBio announced definitive plans to spin off its biopharma operations into a new public company, First Tracks Biotherapeutics, targeted for Q2 2026, potentially as early as late-April. The existing AnaptysBio will become a royalty management company, retaining its name and focusing on collaborations with GSK (Jemperli) and Vanda (imsidolimab). This strategic separation is intended to unlock and amplify value for investors by creating two independent entities with distinct business objectives. The company also reported its fourth quarter and full year 2025 financial results, including a Q4 net income of $49.614 million, and highlighted strong commercial performance for Jemperli, which exited Q4 2025 on a ~$1.4 billion annualized run rate. This corporate restructuring is a highly material event that fundamentally alters the investment thesis for ANAB, allowing for separate valuation of its royalty assets and its clinical pipeline. Traders will closely monitor the progress of the spin-off, including the final timing and details of the share distribution for First Tracks Biotherapeutics.
At the time of this announcement, ANAB was trading at $52.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $13.99 to $57.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.